Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2024-12-02 Major Shareholding Noti…
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for an entity (Swedbank Robur Fonder AB) in another company (Xvivo Perfusion Aktiebolag). It explicitly lists the number of shares and voting rights before and after a transaction, noting the reason for flagging as 'Köp' (Buy) and crossing a threshold (5%). This structure perfectly matches the definition of a Major Shareholding Notification, which reports changes in significant ownership levels crossing defined thresholds. This corresponds to the code MRQ.
2024-12-02 Swedish
XVIVO Perfusion appoints Lena Hagman as deputy CEO
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Lena Hagman as the deputy CEO of XVIVO Perfusion AB. This falls directly under the category of management changes, which is defined as the announcement of changes in the company's board of directors or senior management.
2024-11-14 English
XVIVO Perfusion utser Lena Hagman till vice verkställande direktör
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Lena Hagman as the new Deputy CEO (vice verkställande direktör) of XVIVO Perfusion AB. This falls under the category of management changes, which is explicitly defined as 'Board/Management Information' (MANG).
2024-11-14 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January–September 2024 for XVIVO Perfusion AB. It contains comprehensive financial statements, key performance indicators (EBIT, EBITDA, net sales), management commentary (VD-ord), and business updates. It is a full quarterly report, not an announcement or a summary, and thus fits the definition of an Interim/Quarterly Report. 9M 2024
2024-10-24 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January – September 2024' and 'Q3 2024 Interim report'. It contains comprehensive financial statements, key ratios, management commentary, and operational highlights for the specified period. It is clearly a quarterly financial report, not an announcement of a report or a simple earnings release, as it provides detailed financial data and analysis. 9M 2024
2024-10-24 English
XVIVO förvärvar en unik kommunikationsplattform för transplantationsprocessen
Regulatory Filings Classification · 100% confidence The document is a press release announcing that XVIVO Perfusion AB has signed an agreement to acquire a digital communication and workflow tool (FlowHawk) from Healthtech Solutions Inc. (OmniLife). It details the strategic rationale, financial terms (purchase price, expected revenue contribution, transaction costs), and closing conditions. This type of announcement, detailing a significant corporate transaction like an acquisition, falls under the category of M&A Activity (TAR). It is not a standard periodic report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), as it specifically concerns a takeover/merger proposal. Checking the definitions: - TAR (M&A Activity): Announcements and documents related to merger proposals or takeover bids. This fits perfectly as it is an announcement of an acquisition. - The document length is 5701 characters, which is substantial enough to be the primary announcement itself, not just a short notice (RPA/RNS).
2024-09-19 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.